NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

Key Takeaway: The NCCN has updated its guidelines to recommend ctDNA-MRD testing using Signatera™ technology for bladder cancer. This marks a significant advancement in the management of bladder cancer, reflecting the growing importance of personalized medicine. The recommendation aims to enhance patient outcomes through more accurate monitoring and treatment strategies.